Kentucky Attorney General Andy Beshear claims the three major insulin manufacturers violated the state’s consumer protection law when they raised the price of insulin at the expense of taxpayers. The three insulin companies control 96 percent of the insulin market, Mr. Beshear said.
Eli Lilly, Sanofi and Novo Nordisk have raised the price of insulin products to an average of $300, although production costs are less than $7 per vial, the lawsuit alleges.
“It is truly heartbreaking that Kentuckians are suffering, sometimes risking life and limb, because they cannot afford their medications,” Mr. Beshear told The Hill. “The outrageous actions of these drug companies is a big reason we all pay too much for prescription drugs, and I am insisting they pay up for putting profits ahead of our Kentucky families.”
More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
